心血管疾病中监测抗血小板药物指标的研究进展
被引量:5
摘要
阿司匹林是至今发现的活性最强的内源性血小板抑制剂之一,能抑制二磷酸腺苷(ADP)胶原等诱导的血小板聚集和释放。心血管疾病多使用阿司匹林等抗血小板药物进行抗栓治疗,其传统监测指标主要依赖测定血小板聚集性的高低来进行药物剂量的调整。由于近年来治疗手段的不断提高,氯吡格雷、普拉格雷、西洛他唑等不同作用机制抗血小板药不断问世。
出处
《中国老年学杂志》
CAS
CSCD
北大核心
2012年第22期5100-5102,共3页
Chinese Journal of Gerontology
参考文献20
-
1Tousoulis D,Antoniades C,Nikolopoulou A,et al.Interaction between cy-tokines and sCD40L in patients with stable and unstable coronary syn-dromes[J].Eur J Clin Invest,2007;37(8):623-8.
-
2Welt FG,Rogers SD,Zhang X,et al.GPⅡb/Ⅲa inhibition with eptifibatide lowers levels of soluble CD40L and RANTES after percutaneous coronary intervention[J].Catheter Cardiovasc Interv,2004;61(2):185-9.
-
3Obradovic SD,Antovic JP,Antonijevic NM,et al.Elevations in soluble CD40 ligand in patients with high platelet aggregability undergoing percu-taneous coronary intervention[J].Blood Coagul Fibrinolysis,2009;20(4):283-9.
-
4Yip HK,Chang LT,Sun CK,et al.Impact of clopidogrel on suppression of circulating levels of soluble CD40 ligand in patients with unstable angina undergoing coronary stenting[J].Am J Cardiol,2006;97(2):192-4.
-
5Azar RR,Kassab R,Zoghbi A,et al.Effects of clopidogrel on soluble CD40 ligand and on high-sensitivity C-reactive protein in patients with stable coronary artery disease[J].Am Heart J,2006;151(2):521.
-
6Riondino S,Martini F,La Farina F,et al.Increased plasma levels of solu-ble CD40 ligand correlate with platelet activation markers and underline the need for standardized pre-analytical conditions[J].Clin Biochem,2010;43(7-8):666-70.
-
7Derosa G,D'Angelo A,Scalise F,et al.Comparison between metallopro-teinases-2 and-9 in healthy subjects,diabetics,and subjects with acute coronary syndrome[J].Heart Vessels,2007;22(6):361-70.
-
8Hua Y,Xue J,Sun F,et al.Aspirin inhibits MMP-2 and MMP-9 expres-sions and activities through upregulation of PPARalpha/gamma and TIMP gene expressions in ox-LDL-stimulated macrophages derived from human monocytes[J].Pharmacology,2009;83(1):18-25.
-
9孟晓萍,王素香,张基昌,李震霄,耿丽,殷春媛.普罗布考联合降脂药物对动脉粥样硬化病人的干预治疗[J].中华医学杂志,2009,89(28):1986-1988. 被引量:37
-
10Lu L,Liu H,Peng J,et al.Regulations of the key mediators in inflamma-tion and atherosclerosis by aspirin in human macrophages[J].Lipids Health Dis,2010;9:16-23.
二级参考文献14
-
1蒋兴亮,周京国,唐中,张均.冠心病患者对氧磷酯酶1活性与氧化型低密度脂蛋白的关系[J].中华老年心脑血管病杂志,2004,6(5):305-307. 被引量:8
-
2王家宏,黄永麟,赵敏,曹峰林.厄贝沙坦抑制兔动脉球囊损伤后再狭窄的作用及机理研究[J].中华医学杂志,2006,86(34):2395-2398. 被引量:1
-
3GUO Yi,WANG Qi-zhang,TANG Bing-shan,ZUO Yan-fang,LI Fang-ming,JIANG Xin,WANG Ling,MA Ke-fu.Effects of aspirin on atherosclerosis and the cyclooxygenase-2 expression in atherosclerotic rabbits[J].Chinese Medical Journal,2006(21):1808-1814. 被引量:17
-
4李震,杨跃进,秦学文,阮英茆,陈曦,孟亮,张惠东.通心络与辛伐他汀对兔粥样硬化斑块不稳定性干预的对比研究[J].中华医学杂志,2006,86(44):3146-3150. 被引量:12
-
5Tao CW,Yung HC,Hsin BL.Carvedilol,a pharmacolngical antioxidant,inhibits neointimal matrix metaUaproteinaso-2 and -9 in experimental atherosclerosis.Free Bad Biolo Med,2007,43:1508-1522.
-
6Zorina SG,Kazubiko A,Denis G,et al.N-Acetyl-cysteine decrease the matrix-degrading capacity of macrophage derive foam cell,Circulation,1998,97:2445-2453.
-
7Derosa G,D'Angelo A,Scalise F,et al.Comparison between metallopmteinases-2 and -9 in healthy subjects,diabetics,and subjects with acute coronary syndrome.Heart Vessels,2007,22:361-370.
-
8Sawayama Y,Tatsukawa M,Kikuchi K,et al.Effect on carotid atherosclerosis of probucol plus levofloxacin for chlamydia pneumoniae infection.J Infect Chem,2007,13:92-98.
-
9Iqbal M,Oknzaki Y,Okada S,et al.Probueol modulates iron nitrilotriacetate (Fe-NTA)-dependent renal carcinogenesis and hyperprollferative response:diminution of oxidative stress.Mol Cell Biochem.2007,304:61-69.
-
10Yoshikawa T,Mitani K,Kotosai K,et al.Antiatherogenic effects of cilostazol and probucol alone,and in combination in low density lipoprotein receptor-deficient mice fed with a high fat diet.Horm Metab Res,2008,40:473-478.
共引文献45
-
1廖伟光,欧玉英,梁爱荣,李锦萍,廖淑莲,梁锡权.颈动脉粥样硬化高危患者应用纤维膳食干预效果的研究[J].中华临床医师杂志(电子版),2011,5(18):5336-5340. 被引量:3
-
2白建刚,朱伟平.阿司匹林药理作用研究新进展[J].中国药事,2008,22(10):924-926. 被引量:9
-
3李小刚.抗氧化剂的临床应用现状[J].中国卒中杂志,2010,5(2):139-145. 被引量:11
-
4刘汉华,晏凯利,胡晓军,陈苏,陈娟.普罗布考对急性冠脉综合征患者颈动脉粥样硬化斑块稳定性及血清hs-CRP和MMP-9的影响[J].实用医学杂志,2010,26(12):2199-2201. 被引量:12
-
5董莉.小剂量阿司匹林对高血压患者颈动脉内-中膜厚度及hs-CRP的影响[J].中国实用医药,2010,5(24):152-153. 被引量:1
-
6高菊华,高小平.细胞外基质、基质金属蛋白酶和颈动脉易损斑块[J].国际神经病学神经外科学杂志,2010,37(4):323-325. 被引量:5
-
7邱满堂,吴晓燕,戚晓红.阿司匹林抑制动脉粥样硬化作用机制的研究进展[J].现代生物医学进展,2010,10(19):3757-3759. 被引量:7
-
8徐晓娜,李广平.普罗布考对兔动脉粥样硬化模型C反应蛋白水平的影响及其与斑块稳定性的关系[J].中国心血管杂志,2011,16(4):301-304. 被引量:8
-
9赵林双,向光大,廖玉华,杨李,乐岭,刘晔,孙慧伶.氟伐他汀联合普罗布考对糖尿病心肌病患者8-羟基脱氧鸟苷酸及心功能的影响[J].华南国防医学杂志,2011,25(5):395-398. 被引量:4
-
10宋敏.小剂量阿司匹林对高血压患者动脉粥样斑块进展干预的研究[J].中国现代药物应用,2012,6(3):74-75. 被引量:2
同被引文献43
-
1刘兆平.阿司匹林在心血管疾病预防中的地位:阿司匹林抵抗的影响[J].中国医学前沿杂志(电子版),2008(1):48-51. 被引量:1
-
2武艺.心血管疾病血小板糖蛋白Ⅱb/Ⅲa受体的研究进展[J].国外医学(心血管疾病分册),1996,23(3):151-153. 被引量:5
-
3蒙碧波,吕传柱,蒋宜颖.直接凝血酶抑制剂及其在心血管疾病中的应用[J].中国心血管病研究,2006,4(1):72-75. 被引量:30
-
4A H Gershlick,G Richardson,李崇剑(译),高润霖(校).药物洗脱支架 中断双重抗血小板药物治疗前应咨询心血管病专家[J].英国医学杂志中文版,2007,10(2):73-74. 被引量:1
-
5Torbicki A, Perrier A, Konstantinides S. Guidelines on the diagno- sis and management of acute pulmonary embolism: the Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology ( ESC ) [ J ]. Eur Heart J, 2008,29 ( 11 ) :2276-2315.
-
6Meneveau N, Ming LP, Seronde MF, et al. In hospital and long term outcome after sub-massive and massive pulmonary embolism submitted to thrombolytic therapy [ J ]. Eur Heart J, 2013,24 ( 5 ) : 1447-1454.
-
7Goldhaber SZ, Visani L, De Rosa M, et al. Acute pulmonary em- bolism:clinical outcomes in the International Cooperative Pulmo- nary Embolism Registry(ICOPER) [ J]. Lancet,2011,353 ( 12 ) : 1386-1389.
-
8Giannitsis E, Muller-Bardoeff M, Kurowski V, ct al. Independent prognostic value of cardiac tropnin T in patients with confirmed pulmonary embolism [ J ]. Circulation,2010,102 (5) :211-217.
-
9陈灏珠,钟南山,陆再英主编.内科学.第8版.北京:人民卫生出版社,2013.524.
-
10van den Born B J, lwenberg E C, van der Hoeven N V,et al.Endothelial dysfunction, platelet activation, thrombogenesis and fibrinolysis in patients with hypertensivecrisis. J Hypertens,2011,29 (5) :922-927.
引证文献5
-
1梁卫娟,纪成.阿司匹林预防长期卧床患者并发肺栓塞的临床观察[J].中国基层医药,2014,21(22):3475-3476. 被引量:1
-
2梁智.P选择素、高敏C反应蛋白、血小板在冠心病及急性心梗的意义[J].标记免疫分析与临床,2015,22(7):643-645. 被引量:5
-
3滑艳.心血管疾病抗血小板药物治疗研究进展[J].湖北民族学院学报(医学版),2016,33(4):82-84. 被引量:1
-
4于金婵.心血管疾病抗血小板药物治疗研究进展[J].中西医结合心血管病电子杂志,2017,5(12):24-25. 被引量:1
-
5李电优.心血管疾病临床抗栓治疗的新进展[J].大家健康(学术版),2014(3):99-100. 被引量:2
二级引证文献10
-
1王鹏飞,刘培敏,刘再宇,杜玉芝.不同剂量阿托伐他汀对心肌梗死患者PCI后相关指标及主要不良心血管事件的影响[J].中国药房,2016,27(15):2045-2048. 被引量:33
-
2赵志远.心血管疾病临床抗栓治疗的新进展[J].现代养生,2016,0(12):55-55.
-
3王欢欢,黄继江,邱忠进,陈强,宫海滨.冠脉搭桥术前检测凝血指标对术后出血量判断的价值[J].山西医科大学学报,2016,47(11):995-997. 被引量:1
-
4谢佰华,高盛富,何燕红,陆叶容,吴爱华.PAF和CRP水平在原发性高血压患者心脑血管内皮损伤及病情进展中的作用[J].中国当代医药,2017,24(1):68-70.
-
5郭锦军,王玉亭,于洪伟.血浆可溶性OX40配体对冠状动脉介入治疗后心血管事件的预测价值[J].循证医学,2017,17(1):55-58. 被引量:1
-
6唐银辉.用低分子肝素预防肺源性心脏病患者发生血栓的研究进展[J].当代医药论丛,2018,16(2):26-28. 被引量:4
-
7刘慧招.长期卧床患者应用阿司匹林防治肺栓塞并发症的疗效[J].中国处方药,2016,14(10):62-63.
-
8李晓燕.阿司匹林药物对心血管疾病患者防治效果影响[J].甘肃科技纵横,2017,46(9):88-90. 被引量:1
-
9黄潆莹,林波,龙雪莲.心血管疾病治疗的研究和进展[J].医学食疗与健康,2019,0(4):215-216.
-
10潘燕,朱艳彬,牟晓梅.超敏C反应蛋白(hs-CRP)在脑梗死中诊断和病情评估的探究[J].中国实验诊断学,2019,0(6):957-959. 被引量:17
-
1孟兆平.丹红注射液治疗稳定性心绞痛疗效分析[J].中国医药导刊,2010,12(6):979-980. 被引量:2
-
2王吉云.阿司匹林治疗心血管疾病:性价比最好[J].家庭用药,2004(11):13-13.
-
3梁真如.冠心病的早期防治[J].环境,1993(6):12-13.
-
4李军.血小板抑制剂仅适用于部分不稳定性心绞痛患者[J].国外医学情报,2000,21(5):41-42.
-
5杨铁骊.血小板抑制剂在冠心病医治中的应用[J].天中学刊,2001,16(5):49-51.
-
6陈蕾.应用血小板抑制剂及血管扩张剂治疗过敏性紫癜[J].吉林医学,2004,25(4):93-93. 被引量:2
-
7陈小林,刘婷婷,余泽洪,汤立军,王晓霞.国产氯吡格雷治疗急性冠脉综合征的有效性和安全性[J].中国医药导报,2011,8(11):64-66. 被引量:5
-
8刘乃忠.抗凝药物在心血管疾病中应用的进展[J].天津药学,2001,13(B12):10-11.
-
9刘玉华,杨华英.变异性心绞痛药物治疗近况[J].实用心脑肺血管病杂志,2003,11(3):172-173. 被引量:3
-
10张全贵.参松养心胶囊治疗冠心病心绞痛伴室性早搏的临床疗效[J].中国动脉硬化杂志,2009,17(7):609-609.